Loading...
Guest User
Welcome! Please login.
* - Tentative Dates
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | To part finance working capital requirement of the company | 20.65 |
| 2 | Set off amount from the outstanding loan given by the promoter to the company, at the rights issue price | 5.00 |
| 3 | Set off amount from the outstanding unsecured advance received from Bougainvillea Investments Private Limited (BIPL) by allotting equity shares, at the rights issue price, against rights entitlement and any additional rights entitlement acquired | 12.75 |
| 4 | To meet General corporate purposes | 11.48 |
| Total | 49.88 |
| Period Ended | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|
| Assets | 235.03 | 155.96 |
| Total Income | 167.44 | 167.41 |
| Profit After Tax | 10.42 | 11.93 |
| Amount in ₹ Crore | ||
Indrayani Biotech Limited is a diversified company with a presence across multiple sectors, including food and hospitality, dairy, healthcare and pharmaceuticals, engineering, biotechnology, agriculture, and infrastructure.
The company began its operations with a primary focus on agriculture and biotechnology, particularly in areas such as tissue culture and floriculture. Over the years, it has transitioned into a multi-sector enterprise by consolidating various independent business units under a single organizational structure.
Its strategy emphasizes partnering with experienced entrepreneurs and incorporating established businesses into its portfolio. Through this approach, the company aims to foster growth, improve operational efficiencies, and create long-term value by leveraging opportunities across a broad range of industries.
